The classic IMpassion130 (Emens et al. 2021) and IMpassion131 (Gianni et al. 2022) randomized controlled phase III clinical trials were conducted to analyze the predictive value of PD-L1 for the efficacy of atezolizumab monoclonal antibody in advanced triple-negative breast cancer immunotherapy, and it was found that the immune combined with chemotherapy (OS = 25.4 months) significantly improved the prognosis of patients with PD-L1 positive patients compared with chemotherapy (OS = 17.9 months) (HR = 0.67, 95%CI: 0.53–0.86). Here, CD274 is linked to triple-negative breast carcinoma.